Subject: NIH GUIDE - Vol. 20, No. 11, March 15, 1991
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 14 Mar 91 13:15 EST

Hi Paul,
   Here's the latest NIH Guide.   There will be two additional items
send to you today from the Guide for posting.
    Please post this to the NIH Listserver as: NIHGUIDE.910315
And notify me when all are posted.
     Thanks.    Dottie
 ---------------------------- Text of forwarded message -----------------------
 
$$XID NIHGUIDE 19910315 V20N11 P1O1 ************************************
X-comment: RFAs described: OD-91-02, ES-91-02
 
$$INDEX BEGIN **********************************************************
 
NIH GUIDE - Vol. 20, No. 11, March 15, 1991
 
                                   NOTICES
 
$$INDEX N1 *************************************************************
 
INCREASE IN TRAINING FUNDS FOR FY 1991
National Institute on Drug Abuse
Index:  DRUG ABUSE
 
                   NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 *************************************************************
 
DETERMINANTS OF PERMANENT TOOTH LOSS IN THE U.S.A. (RFP)
National Institute of Dental Research
Index:  DENTAL RESEARCH
 
$$INDEX R2 *************************************************************
 
DEVELOPMENTAL STUDIES HYBRIDOMA BANK (RFP)
National Institute of Child Health and Human Development
Index:  CHILD HEALTH, HUMAN DEVELOPMENT
 
$$INDEX R3 05/24/91 ****************************************************
 
CONSTRUCTION OF MOUSE PRODUCTION FACILITIES (RFA OD-91-02)
National Institutes of Health
Index:  NATIONAL INSTITUTES OF HEALTH
 
$$INDEX R4 06/13/91 ****************************************************
 
SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM (RFA ES-91-02)
National Institute of Environmental Health Sciences
Index:  ENVIRONMENTAL HEALTH SCIENCES
 
                        ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 *************************************************************
 
VULNERABILITY TO DRUG ABUSE (PA-91-33)
National Institute on Drug Abuse
Index:  DRUG ABUSE
 
$$INDEX P2 *************************************************************
 
INDIVIDUAL POSTDOCTORAL FELLOWSHIPS AND SENIOR FELLOWSHIPS IN
HEMATOLOGIC RESEARCH (PA-91-34)
National Institute of Diabetes and Digestive and Kidney Diseases
National Heart, Lung, and Blood Institute
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES, HEART,
        LUNG, BLOOD
 
$$INDEX END ************************************************************
 
                                   NOTICES
 
$$N1 BEGIN *************************************************************
 
INCREASE IN TRAINING FUNDS FOR FY 1991
 
P.T. 22, 44; K.W. 0720005, 0404009, 0785055, 0785035, 0715008
 
National Institute on Drug Abuse
 
In order to address the shortage of basic, epidemiologic, and clinical
research scientists in the area of substance abuse and addiction, the
research training budget for FY 1991 has been significantly increased
for the National Institute on Drug Abuse (NIDA).  As a result, NIDA is
seeking additional applications for all of its basic, epidemiologic, and
clinical research training programs.  These programs include the
following predoctoral and postdoctoral support mechanisms:  National
Research Service Awards for Institutional Grants, National Research
Service Awards for Individual Fellows, National Research Service Awards
for Research Training for Individual Fellows in Human Immunodeficiency
Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS), and
National Research Service Awards for Institutional Research Training
Grants in Human Immunodeficiency Virus (HIV) Infection and Acquired
Immunodeficiency Syndrome (AIDS).  Applications for these awards
received on or prior to May 10, 1991, will receive an expedited review
to allow their consideration for funding prior to October 1, 1991.  The
specific program announcements can be obtained from the Grants
Management Branch, OPRM, NIDA, Room 8A-54, 5600 Fishers Lane, Rockville,
Maryland 20857 (301) 443-6710.  The application kits may be obtained
from the Division of Research Grants, NIH, Westwood Building, Room 449,
5333 Westbard Avenue, Bethesda, MD 20892, (301) 496-7441.  The original
and five copies of the application must be sent to:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
In order to assist us with the expedited review process, please send an
additional courtesy copy of your application under separate cover to:
 
Director, Office of Extramural Program Review
National Institute on Drug Abuse
Parklawn Building, Room 10-42
5600 Fisher's Lane
Rockville, MD  20857
 
$$N1 END ***************************************************************
 
                   NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN NIH-NIDR-2-91-6R ********************************************
 
DETERMINANTS OF PERMANENT TOOTH LOSS IN THE U.S.A.
 
RFP AVAILABLE:  NIH-NIDR-2-91-6R
 
P.T. 34; K.W. 0715148, 0715020, 0785040, 0411005
 
National Institute of Dental Research
 
The National Institute of Dental Research has a requirement for a
three-year study, conducted in two phases, to measure permanent tooth
loss and the factors that influence it.  The first phase shall collect
data that describe the biological condition of extracted teeth;
socioeconomic, attitudinal, economic, and dental care-seeking
characteristics of persons having extractions; and selected
characteristics of the dental providers who perform extractions.
Results from phase 1 shall be representative of tooth loss occurring at
dental settings among the civilian non-institutionalized populations in
at least two, but not more than four, states from different regions in
the U.S.A. The second phase shall analyze the personal, social,
cultural, economic, and provider factors that influence the choice
between extraction and alternative treatments, controlling for the
biological condition of the teeth.  In this phase, data shall be
collected from patients whose teeth were treated with dental services
that are alternatives to extraction for given biological conditions.
The data from both phase 1 and phase 2 shall be used to analyze the
relative importance of factors that influence the choice between
extraction and alternatives.
 
This is an announcement for an anticipated Request for Proposals (RFP).
It is expected that one award will be made.  RFP No. NIH-NIDR-2-91-6R
will be available approximately April 1, 1991, with a closing date
tentatively set for May 17, 1991.  Requests for the RFP must be
submitted in writing, addressed to:
 
Marion L. Blevins
Contract Management Section
National Institute of Dental Research
National Institutes of Health
Westwood Building, Room 521
Bethesda, MD  20892
 
$$R1 END ***************************************************************
 
$$R2 BEGIN NICHD-CRMC-91-04 ********************************************
 
DEVELOPMENTAL STUDIES HYBRIDOMA BANK
 
RFP AVAILABLE:  NICHD-CRMC-91-04
 
P.T. 34; K.W. 0760030, 0775000, 0760020, 0760045, 0710070, 0780000
 
National Institute of Child Health and Human Development
 
The National Institute of Child Health and Human Development (NICHD) is
planning to continue and expand a Developmental Studies Hybridoma Bank
(DSHB).  The DSHB shall maintain a reserve of monoclonal antibodies that
are used for research in developmental biology.  The monoclonal
antibodies included in the DSHB shall be directed towards molecules that
are important in developmental processes.  Expansion is desired in the
banking of hybridomas that produce antibodies to molecules that have
significance in the development of the human immune system, that are
important oncogenic proteins, and that function as growth factors.  The
successful contractor shall maintain the current stock, acquire and
develop new products, and sell and distribute the antibody products.
The successful contractor will also indicate a capability in sales
management in order to increase the revenues of the DSHB, which is
partially self-supporting.  The antibodies will be made available to
qualified investigators to support and facilitate research that will
lead to an improved understanding of the mechanisms of development.
 
This solicitation is a competitive renewal.  The issuance of the Request
for Proposals (RFP) will be on or about March 4, 1991, and proposals are
due by 4:00 pm (Local Time), May 6, 1991.  The Institute plans to make
one award from this solicitation.  Those organizations desiring a copy
of the RFP must send a written request to Miss Virginia A. DeSeau at the
address listed below.  All requests must cite the RFP number above and
include two self-addressed mailing labels.  All sources who consider
themselves qualified are encouraged to submit proposals.
 
Staff Contact:
 
Virginia A. DeSeau
National Institute of Child Health and Human Development
Executive Plaza North, Room 515
6130 Executive Boulevard
Rockville, MD  20852
Telephone:  (301) 496-4611
 
$$R2 END ***************************************************************
 
$$R3 BEGIN OD-91-02 FULL-TEXT ******************************************
 
CONSTRUCTION OF MOUSE PRODUCTION FACILITIES
 
RFA AVAILABLE:  OD-91-02
 
P.T. 34; K.W. 1002002, 1014002, 1014006
 
National Institutes of Health
 
Letter of Intent Receipt Date:  April 15, 1991
Application Receipt Date:  May 24, 1991
 
BACKGROUND INFORMATION
 
The Department of Labor, Health and Human Services, and Education, and
Related Agencies Appropriations for 1991, provided $14,800,000 to the
Office of the Director, NIH, for "extramural facilities construction
grants if awarded competitively..."; the report language cited mouse
production facilities in particular.  Of this amount, $4,800,000 has
been identified for funding two applications that were submitted in
response to a previous solicitation and received high priority scores,
but were not funded in Fiscal Year 1990.
 
Thus, in response to this latest Congressional action, the NIH is
issuing RFA OD-91-02 to solicit construction grant applications for the
construction of large-scale mouse production and mutant characterization
facilities.
 
OBJECTIVES AND SCOPE
 
Support may be requested for the construction of new facilities and
additions or renovations to existing facilities that will be dedicated
to the breeding and production of specialized strains of mice, including
inbred and mutant mice, necessary to meet the Nation's needs in
conducting biomedical research on a broad range of topics.  Associated
fixed equipment necessary for operation of these facilities may also be
requested as part of the application.
 
MECHANISM OF SUPPORT
 
Any domestic, non-Federal public or non-profit private institution,
organization, or association that conducts or supports biomedical
research is eligible to apply.
 
NIH staff will verify application and award eligibility.  Those judged
to be unresponsive or ineligible will be returned to the investigator.
 
The award mechanism will be the construction grant award.  Awards will
be administered under Federal Regulation 45 CFR Part 74 - Administration
of Grants, and 42 CFR Part 52 for cancer construction projects, and PL
101-190.
 
This one-time solicitation based on the Fiscal Year 1991 appropriation
will make available up to $10,000,000 for this initiative.  Final amount
to be determined will be based on the peer-review evaluation and the
judgment of the Director, NIH.  Up to 75 percent of the allowable costs
of a project may be provided, not to exceed $10,000,000.  The matching
contributions by the institution may be in cash and in kind, fairly
evaluated, including plant and equipment or services throughout the
required 20-year period of usage of the facility (and including such
specialized strains of mice as the Secretary, HHS, may request for
purposes of biomedical research).  Amounts provided by any agency of the
Federal government, other than the Department of Health and Human
Services, and services assisted or subsidized by any such agency, may be
included in the amount of such matching funds.  Prior to a grant award,
the applicant must provide an assurance of required matching funds and
that other funds have been secured to meet any projected costs in excess
of the award amount.  Requests of less than $500,000 will not be
accepted.  No indirect costs or continuation costs will be awarded.
 
For additional information, a copy of the complete RFA and application
materials (Standard Form 424), please contact:
 
Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD  20892
Telephone:  (301) 496-8534
 
Grants for research facilities construction programs of the National
Institutes of Health are subject to Executive Order 12372.  All awards
will be made either under the authority of the Public Health Service
Act, Title IV, Section 413(b)6(A) as amended by Public Law 99-158 (42
USC 285a-2) and administered under PHS grant policies and Federal
Regulations 42 CFR Part 52b and 45 CFR Part 74 and Public Law 101-190.
This program is described in the Catalog of Federal Domestic Assistance,
Number 93.392, Cancer-Construction.
 
$$R3 END ***************************************************************
 
$$R4 BEGIN ES-91-02 FULL-TEXT ******************************************
 
SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM
 
RFA AVAILABLE:  ES-91-02
 
P.T. 34; K.W. 1007003, 1007009, 1002016, 0760003, 0755020, 0710030
 
National Institute of Environmental Health Sciences
 
Letter of Intent Receipt Date:  May 1, 1991
Application Receipt Date:  June 13, 1991
 
PURPOSE
 
The National Institute of Environmental Health Sciences (NIEHS)
announces the availablity of funds for the continuation of a special
Program of basic research and training grants directed towards
understanding, assessing, and attenuating the adverse effects on human
health resulting from exposure to hazardous substances.  Grants made
under this Program will be for coordinated, multicomponent,
interdisciplinary programs.  The objective is to establish and maintain
a unique program linking biomedical research with related engineering,
hydrogeologic, and ecologic components.
 
The Superfund Amendments and Reauthorization Act (SARA) of 1986
established a university-based program of basic research within the
NIEHS.  The NIEHS interprets its mandate under SARA to include funding
for engineering, ecological, and hydrogeological research, and will
support projects in these areas if they are to be performed in
conjunction with biomedically related programs.  The NIEHS hopes to
encourage true collaborative efforts among researchers in these various
areas.
 
RESEARCH OBJECTIVES AND SCOPE
 
The NIEHS Superfund Basic Research Program is intended to foster the
growth of collaborative multidisciplinary research programs aimed at
understanding health and environmental effects associated with hazardous
waste sites and at developing improved technologies for cleaning up
these sites.  The focus of this Program is the effects on human health.
 
Strong biomedical research is a requisite of this Program.  A minimum of
three approved biomedical projects is required for funding.  The Program
expects that the non-biomedical research will be an integral part of the
overall effort.  All applications considered for funding must contain
approved projects in both biomedical and non-biomedical areas.  Further,
the NIEHS intends to support graduate and advanced training in
environmental and occupational health and safety, the engineering
aspects of hazardous waste control, and geosciences in the setting of
the research program.
 
Awards made under this announcement will be for a three-year period.
The authorized funding level is $35 million per year.  These dollar
amounts are budget ceilings and actual amounts will be appropriated each
year, according to the Federal budget process.  Because the funding
level of this program may vary from that authorized, actual award levels
for approved and funded applications will be based on program balance
and the availability of funds, in addition to the scientific merit
considerations of the review process.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations.  If women and minorities are not included in the study
populations for clinical studies, a specific justification for this
exclusion must be provided.  Applications without such documentation
will not be accepted for review.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas.  This Request for
Applications, Superfund Hazardous Substances Basic Research Program, is
related to the priority area of environmental health.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, D.C. 20402-9325 (telephone
202-783-3238).
 
MECHANISM OF SUPPORT
 
The mechanism of support will be the P42 multiproject grant-in-aid for a
period not to exceed three years, starting in FY 92.  Administrative
adjustments may be necessary to make the funding periods coincide with
this time frame.  It is anticipated that approximately 40 awards will be
made.
 
THIS PROGRAM IS NOT INTENDED TO SUPPORT INDIVIDUAL RESEARCH PROJECT
GRANTS.
 
METHOD OF APPLYING
 
Letters of Intent
 
Prospective applicants are asked to submit a brief letter of intent that
includes a descriptive title of the research and responsible
investigators, and identification of any other participating
institutions.  This letter must be received no later than MAY 1, 1991.
 
Application Procedure
 
Applications are to be submitted on form PHS 398 (revised 10/88).  Forms
are available from the Division of Research Grants, National Institutes
of Health, Westwood Building, Room 240, 5333 Westbard Avenue, Bethesda,
MD 20892-4500.
 
Applications must be RECEIVED at the NIEHS by JUNE 13, 1991.
 
THIS ANNOUNCEMENT DOES NOT CONTAIN COMPLETE APPLICATION INSTRUCTIONS FOR
THIS RFA.  PLEASE CONTACT PROGRAM STAFF AT NIEHS FOR FURTHER
INFORMATION.
 
INQUIRIES
 
A copy of the complete RFA and program guidelines and inquiries should
be directed to:
 
William A. Suk, Ph.D., M.P.H.
Program Administrator, Superfund Basic Research Program
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC  27709
Telephone:  (919) 541-0797
 
Grants management inquiries should be directed to:
 
David L. Mineo
Chief, Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC  27709
Telephone:  (919) 541-1373
 
$$R4 END ***************************************************************
 
                        ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN *************************************************************
 
VULNERABILITY TO DRUG ABUSE
 
PA:  PA-91-33
 
P.T. 34; K.W. 0404009, 0411005, 0755030
 
National Institute on Drug Abuse
 
Purpose:  The etiology research program supports studies that focus on
the origins of drug abuse answering questions about the causal patterns
and factors leading to drug abuse.  An understanding of the factors that
predispose or protect an individual from drug abuse is essential to the
successful prevention of drug abuse.  "Vulnerability" refers to the fact
that individuals are differentially at risk for engaging in drug use and
for making the transition from drug use to drug abuse.  A primary goal
of the vulnerability research area is to develop the necessary
information, theories, and methodologies to identify individuals at high
risk for drug abuse.  Vulnerability to the transition from drug use to
abuse, and the origins of drug abuse and drug dependence, as opposed to
casual, limited experimentation, are the targets of this program.  Drug
abusers are a heterogeneous group and there are multiple patterns of
abuse, each possibly having multiple potential etiologies.  An
understanding of the etiology of drug abuse will make it possible to
determine the critical causal factors and the most effective targets of
intervention.
 
Areas of Research Interest:  The following are representative areas of
research interest.
 
  o  Behavioral Genetics Studies:  Research in this area would focus on
     studies of the heritability, mechanisms, and markers of
     biologically based factors predisposing an individual to, or
     protecting an individual from, drug abuse and dependence.  Family,
     twin, adoption, half sibling, and some epidemiological studies may
     be included.
 
  o  Physiological Studies (including neurology and biochemistry):
     Research in this area would focus on studies of the physiological,
     biochemical, and/or neurological correlates, mechanisms, and
     manifestations of inherited, congenital, or acquired predisposing
     biomedical factors.  Biomedical conditions antecedent and/or
     concomitant to drug abuse, altered response to drugs,
     physiologically based deficits leading to impaired psychological
     function or psychopathology, and other related phenomena would also
     be appropriate targets of studies.
 
  o  Psychology/Psychopathology Studies (also including developmental
     psychopathology):  Research in this area would focus on studies of
     the psychological, developmental, and psychopathological factors
     and behaviors involved in the predisposition, initiation,
     escalation, maintenance, and recidivism of drug abuse and
     dependence.  Prodromal markers, developmental stage related
     transitions, mechanisms of predisposition or protection,
     relationships to personality characteristics and to other
     psychopathological conditions (including alcohol abuse),
     methodologies for early identification, principles of intervention
     and remediation, stress responses and the availability and form of
     alternate behaviors and coping skills, and other related phenomena
     would also be appropriate study foci.  The identification of
     developmental stage related high-risk profiles would be an
     additional major goal.
 
  o  Family/Environment/Behavioral Studies:  Research in this area would
     focus on studies of the exogenous factors that are facilitative or
     inhibitive of the initiation, escalation, and maintenance of drug
     abuse and dependence.  Studies in this program component would
     include research on intergenerational and peer modeling and social
     influences; contributions of drug characteristics, availability,
     and delivery factors; impact of social and behavioral sanctions,
     consequences, and enforcement as influences.
 
Research Support Mechanisms:  Support mechanisms include Research
Projects (R01), Small Grants (R03), Conference Grants (R13), First
Independent Research Support and Transition Awards (R29), Program
Projects (P01) and Center Grants (P50).
 
IMPORTANT---The receipt dates appearing later in this announcement are
for the research grant mechanism (R01).  All other support mechanisms
listed above may have their own:  (1) receipt and review date schedule,
(2) special review and award criteria, and/or (3) special programmatic
considerations for funding priority.  Please contact NIDA program and
review staff for further information.
 
Eligibility:  Applications for research grants may be made by public or
private, for-profit or non-profit organizations, such as universities,
colleges, hospitals or laboratories, units of State or local government,
or authorized units of the Federal Government.  Women and minority
investigators, in particular, are encouraged to apply.
 
Application Process:  Applicants must use the current version of the
form PHS 398 (revised 10/88).  The announcement number PA-91-33 and the
title of this announcement:  Vulnerability to Drug Abuse, must be typed
in item #2 on the face page of the application form.  Applications must
adhere to page limitations noted in the application kit.  Complete
instructions for applicants are included in the kit.
 
Application kits containing the necessary forms and instructions may be
obtained from business offices of sponsored research at most
universities, colleges, medical schools, and other major research
facilities.  If such a source is not available, the following office may
be contacted for the necessary application material and announcements:
Division of Research Grants, NIH, Westwood Bldg., Room 449, 5333
Westbard Avenue, Bethesda, Maryland 20892, (301) 496-7441.
 
Review Process:  Applications received under this announcement will be
assigned to an initial review group for scientific merit review.  Such
groups consist primarily of non-Federal experts.  Notification of review
outcome will be sent to the applicant after the initial review.
Applications will receive a secondary review for policy consideration by
the appropriate National Advisory Council.  Only applications
recommended for approval by the National Advisory Council will be
considered for funding.  Applications submitted in response to this
announcement are not subject to the intergovernmental review
requirements of Executive Order 12372, as implemented through Department
of Health and Human Services regulations at 45 CFR Part 100.
 
Application Receipt and Review Schedule:
 
Receipt of            Initial           Advisory       Earliest
Applications          Review            Council        Award Date
 
June 1/July 1*       Oct./Nov.          Jan./Feb.      April
Oct. 1/Nov. 1*       Feb./March         May/June       July
Feb. 1/Mar. 1*       June/July          Sept./Oct      December
 
* New research grants, competing continuations, supplemental, and
revised applications (new or renewal) are to be submitted on these
dates.  Program projects and center applications are due on the earlier
date.
 
Consequences of Late Submission - Applications received after the above
dates are subject to assignment to the next review cycle.
 
Inclusion on Women and Minorities in Clinical Research Study
Populations:
 
Applications/proposals for ADAMHA grants and cooperative agreements are
required to include both women and minorities in study populations for
clinical research, unless compelling scientific or other justification
for not including either women or minorities is provided.  This
requirement is intended to ensure that research findings will be of
benefit to all persons at risk of the disease, disorder, or condition
under study.  For the purpose of these policies, clinical research
involves human studies of etiology, treatment, diagnosis, prevention, or
epidemiology of diseases, disorders or conditions, including but not
limited to clinical trials; and minorities include U.S. racial/ethnic
minority populations (specifically:  American Indians or Alaskan
Natives, Asian/Pacific Islanders, Blacks, and Hispanics).
 
ADAMHA recognizes that it may not be feasible or appropriate in all
clinical research projects to include representation of the full array
of U.S. racial/ethnic minority populations.  However, applicants are
urged to assess carefully the feasibility of including the broadest
possible representation of minority groups.
 
Applications should include a description of the composition of the
proposed study population by gender and racial/ethnic group, and the
rationale for the numbers and kinds of people selected to participate.
This information should be included in the form PHS 398 in Section 2,
A-D of the Research Plan AND summarized in Section 2, E, Human Subjects.
 
Applications should incorporate in their study design gender and/or
minority representation appropriate to the scientific objectives of the
work proposed.  If representation of women or minorities in sufficient
numbers to permit assessment of differential effects is not feasible or
is not appropriate, the reasons for this must be explained and
justified.  The rationale may relate to the purpose of the research, the
health of the subjects, or other compelling circumstances (e.g., if in
the only study population available there is a disproportionate
representation in terms of age distribution, risk factors,
incidence/prevalence, etc., of one gender or minority/majority group).
 
If the required information is not contained within the application, the
application will be returned.  Peer reviewers will address specifically
whether the research plan in the application conforms to these policies.
If gender and/or minority representation/justification are judged to be
inadequate, reviewers will consider this as a deficiency in assigning
the priority score to the application.
 
All applications/proposals for clinical research submitted to ADAMHA are
required to address these policies.  ADAMHA funding components will not
award grants that do not comply with these policies.
 
Availability of Funds:  Both research project grants and center grants
will be awarded based on this announcement.  It is anticipated that 4-5
research projects will be funded under this announcement during FY 1992,
but will depend on availability of funds.  Applications received in
response to this announcement will compete for approximately $2.0
million in new grant money that has been made available for this
purpose.
 
It is estimated that 1 new Vulnerability Center will be funded under
this announcement during FY 1992.  Initiation of new Centers after FY
1992 will depend on availability of funds.  Center applications received
in response to this announcement will compete for approximately $1.5
million in new grant money that has been made available for this
purpose.
 
Further information and consultation on program requirements may be
obtained from:
 
Meyer D. Glantz, Ph.D.
Acting Chief, Etiology Research Section
Prevention Research Branch
Division of Clinical Research
National Institute on Drug Abuse
5600 Fishers Lane, Rockwall Building
Rockville, MD  20857
Telephone:  (301) 443-1514
 
$$P1 END ***************************************************************
 
$$P2 BEGIN *************************************************************
 
INDIVIDUAL POSTDOCTORAL FELLOWSHIPS AND SENIOR FELLOWSHIPS IN
HEMATOLOGIC RESEARCH
 
PA:  PA-91-34
 
P.T. 22; K.W. 0785070, 0715032, 0765035, 1002058, 0790005, 0765030,
0710030
 
National Institute of Diabetes and Digestive and Kidney Diseases
National Heart, Lung, and Blood Institute
 
Application Receipt Dates:  January 10, May 10, September 10
 
This Program Announcement emphasizes the continued interest of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
and the National Heart, Lung, and Blood Institute (NHLBI) in supporting
the development of promising new investigators in fundamental areas of
hematology, as well as in areas representing frontiers of the
application of hematologic knowledge to clinical problems.
 
The NIDDK and the NHLBI currently have active programs supporting
research across the broad area of hematology.  Among the areas of
primary interest, in which additional training needs exist, are
approaches to understanding the fundamental processes underlying the
normal and pathologic function of blood cells and the blood forming
system; hemoglobin structure, function, and molecular genetic
regulation; acquired and inherited hemolytic anemias; membranes and
their role in cellular regulation; iron metabolism, storage, and
transport; hematopoiesis and its regulation by growth factors, including
erythropoietin; characterization of growth factor receptors and
examination of their role in hematopoietic stem cell differentiation;
immunohematology and autoimmune disease; transplant biology; and basic
approaches to gene therapy.  Other research problems related to
disorders of the blood or blood elements are of interest as well.
 
To accomplish the goals of the research programs of the NIDDK and the
NHLBI, scientists who are well trained in one or more of a variety of
disciplines are needed.  Therefore, the NIDDK and the NHLBI are
announcing the availability of individual postdoctoral fellowships to
highly qualified scientists who are seeking training that will enable
them to engage in research relevant to hematologic diseases.  The NIDDK
and the NHLBI also are interested in offering fellowships to scientists
who wish to integrate mathematical, physical, chemical, as well as
computer modeling approaches, with those of clinical, molecular, and
cellular biology in hematologic research.
 
Applications received in response to this announcement will be assigned
to an appropriate institute for funding consideration.  Primary
assignment will be determined by the research proposed in the
application and its relationship to guidelines for referral of
applications, currently in use.  Because of the mutual interests of the
two Institutes in some of the areas listed above, it is recommended that
questions about the assignment of an application be addressed to:
 
Walter Stolz, Ph.D.
Director, Division of Extramural Activities, NIDDK
National Institutes of Health
Bethesda, MD  20892
 
or
 
Ronald Geller, Ph.D.
Director, Division of Extramural Affairs, NHLBI
National Institutes of Health
Bethesda, MD  20892
 
Support for individual postdoctoral fellowships will be provided through
the National Research Service Award (NRSA, F32).  The stipend levels for
the individual postdoctoral fellowships range from $18,600 to $32,300,
depending on the number of years of relevant experience subsequent to
the award of the doctoral degree.  In addition, the training institution
may request an institutional allowance of up to $3,000 per year for
supplies, equipment, travel, tuition, fees, insurance, and other
training-related expenses.  Individual postdoctoral fellowships are made
for a period of up to 3 years.
 
Also encouraged are applications for Senior Fellowships (NRSA, F33).
Investigators who hold a doctorate or equivalent degree and have had at
least seven subsequent years of relevant research or professional
experience are eligible for this award.  The award is designed to
provide opportunities for experienced scientists to make major changes
in the direction of their research careers, to acquire new research
capabilities, to broaden their scientific background, to enlarge their
command of an allied research field, or to take time from regular
professional responsibilities to increase their capabilities for
engaging in health-related research.  The amount of the stipend is based
on the salary from the applicant's home institution but will not exceed
$32,300 per year.
 
Receipt dates for applications are January 10, May 10, and September 10
annually.  The earliest dates that awards can be made are June, October,
and February, respectively.
 
Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center of Research Resources
may wish to identify the Center as a resource for conducting the
proposed research.  In such a case, a letter of agreement from the GCRC
Program Director must be included in the application material.
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis should be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale should be provided.
 
The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research design
and sample size appropriate for the scientific objectives of the study.
This information should be included in the form PHS 398 in Section 2,
A-D of the Research Plan AND summarized in Section 2, E, Human Subjects.
Applicants/offerors are urged to assess carefully the feasibility of
including the broadest possible representation of minority groups.
However, NIH recognizes that it may not be feasible or appropriate in
all research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native Americans
(including American Indians or Alaskan Natives), Asian/Pacific
Islanders, Blacks, Hispanics).
 
The rationale for studies on single minority population groups should be
provided.
 
For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.
 
The usual NIH policies concerning research on human subjects also apply.
Basic research or clinical studies in which human tissues cannot be
identified or linked to individuals are excluded.  However, every effort
should be made to include human tissues from women and racial/ethnic
minorities when it is important to apply the results of the study
broadly, and this should be addressed by applicants.
 
For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.
 
If the required information is not contained within the application, the
application will be returned.
 
Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.
 
All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants or
cooperative agreements that do not comply with these policies.
 
Applications must be submitted on PHS form 416-1 (revised 7/88) that is
available in the business or grants and contracts office at most
academic and research institutions.  In order to identify the
application as a response to this Program Announcement, item 3 of the
application face page must be the title "Availability of Individual
Postdoctoral Fellowships and Senior Fellowships in Hematologic Research,
PA-91-34."  The original and two copies of the application must be
mailed to:
 
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
For additional information about individual postdoctoral fellowship
opportunities available through the NIDDK and the NHLBI, please contact:
 
Charles H. Rodgers, Ph.D.
Manpower Program Director
Division of Kidney, Urologic and Hematologic Diseases
NIDDK
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-7573
 
Fann Harding, Ph.D.
Special Assistant to the Director for Research Training
Division of Blood Diseases and Resources
NHLBI
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-1817
 
For fiscal and administrative matters, contact:
 
Florence D. Cohen
Lead Grants Clerk
Grants Management Branch, DEA
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD  20892
Telephone:  (301) 496-7467
 
These programs are described in the Catalog of Federal Domestic
Assistance No. 93.849 - Kidney, Urologic and Hematologic Diseases
Research.  Awards will be made under the authority of the Public Health
Service Act, Title III, Section 301 (Public Law 78-4110, as amended; 42
USC 241) and administered under PHS grant policies and federal
regulations 42 CFR Part 52, and 45 CFR Part 74.  This program is not
subjected to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.
 
$$P2 END ***************************************************************

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
 
5333 Westbard Avenue
Bethesda, Maryland 20816
 
               FULL TEXT OF RFAs FOR ONLINE ACCESS